CardioInsight 1 RBBB

Launched by CHINESE UNIVERSITY OF HONG KONG · Sep 22, 2022

Keywords

ClinConnect Summary

The CardioInsight 1 RBBB clinical trial is looking at a treatment called cardiac resynchronization therapy (CRT) for patients with heart failure. CRT is a therapy that helps the heart beat more efficiently, but some patients don’t respond well to it. This study aims to find out if adjusting how CRT is delivered can improve outcomes for those who typically don't benefit from the treatment, especially focusing on different patterns of how the heart’s electrical signals are delayed.

To participate in this trial, you need to be an adult aged 18 or older, with heart failure that has either an ischemic (caused by reduced blood flow) or non-ischemic origin. You should have a specific type of heart signal delay (with a QRS duration over 120 ms) and be in a NYHA class III or higher, which means your heart failure symptoms are more severe. Participants will need to have been on stable heart failure medications for at least three months and must give their consent to join the study. However, people with certain heart conditions, pregnant women, or those involved in other studies will not be eligible. If you join, you can expect to receive personalized care and monitoring to help us learn the best way to deliver this therapy.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult (aged 18 or above) of both sexes
• • Ischemic or non-ischemic cause of heart failure
• • QRS duration \> 120 ms, non-left bundle branch block (LBBB) type of conduction disturbance
• • NYHA class III or above
• • Informed consent by the patient
• • Already received stable dose of guideline directed medical therapy for at least 3 months
• Exclusion Criteria:
• • LBBB patients
• • Pregnant women
• • Participation in another study
• • Patient with contraindication to left ventricle catheterization by a retrograde aortic approach